cell neoplasms. Bortezomib, a proteasome inhibitor initially used in multiple myeloma, has been combined with chemotherapy and shown to be effective in frontline PBL. 5 In the relapsed setting, PBL… Click to show full abstract
cell neoplasms. Bortezomib, a proteasome inhibitor initially used in multiple myeloma, has been combined with chemotherapy and shown to be effective in frontline PBL. 5 In the relapsed setting, PBL treatment is even more difficult and new approaches are required. evaluated and doxorubicin in the relapsed All four a and three of the four patients remained in remission for at least 15 A small prospective study conducted by the is examining daratumumab- EPOCH in the front- line setting Based on the data evaluating daratumumab in PBL, we combined this targeted agent with a standard NHL salvage regimen, ICE. In our limited evaluation of four patients, the novel regimen D- ICE, was safe and effective with all four patients achieving a CR after three to four cycles of therapy. The concerning adverse effect was myelosuppression, and research may lead to dosing or frequency changes to the to mitigate this are promising and warrant further evaluation of D- in a prospective
               
Click one of the above tabs to view related content.